Finch Therapeutics

Finch Therapeutics has a portfolio of microbiome assets including CP101, a late-stage, investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI). Additionally, Finch has pre-clinical assets that are designed to target ulcerative colitis, Crohns disease, and autism spectrum disorder. Finch has a robust intellectual property estate reflecting the Companys pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications....

Finch therapeutics operates in the Biotechnology research industry.

Finch therapeutics's revenue is 11m - 100m

Finch therapeutics has 11 - 50 employees.